SCHEMBL3529359

SCHEMBL3529359

CC(C)COC(=O)NC1CCN(c2ccnc(-c3ccccc3O)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.42
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
CKS1B P61024 4/20 0.40
SKP1 P63208 4/20 0.40
SKP2 Q13309 4/20 0.40
PDE10A Q9Y233 1/20 0.40
USP2 O75604 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
SMO Q99835 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534191 0.88 DRD2 (0.41) DRD2ALDH1A1KDM4ETDP1HTR1A
SCHEMBL3531331 0.84 DRD2 (0.43) DRD2ALDH1A1KDM4EHTR1AHTR2A
SCHEMBL1258958 0.82 DRD2 (0.47) DRD2ALDH1A1KDM4ETDP1MAPT
SCHEMBL3532952 0.82 DRD2 (0.43) DRD2ALDH1A1KDM4ETDP1MAPT
SCHEMBL12991337 0.82 ALDH1A1 (0.45) ALDH1A1KDM4ETDP1MAPTL3MBTL1
SCHEMBL12929623 0.80 ALDH1A1 (0.53) DRD2ALDH1A1KDM4EMAPTHTR1A
SCHEMBL13343040 0.80 SMAD3 (0.54) DRD2ALDH1A1KDM4EMAPTL3MBTL1
SCHEMBL937815 0.78 KMT2A (0.43) DRD2ALDH1A1KDM4ETDP1MAPT
SCHEMBL5477619 0.77 DRD2 (0.43) DRD2ALDH1A1MAPTHTR1AHTR2A
SCHEMBL3211335 0.77 DRD2 (0.48) DRD2ALDH1A1MAPTHTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 DRD2 3032/4885ALDH1A1 2382/4885KDM4E 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.